Trial · NCT00907738
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
NCT00907738, Phase 2, Completed, Merck Sharp & Dohme LLC; results first posted 2011-07-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007). Trials, record NCT00907738. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00907738
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
- NCT number
- NCT00907738
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 27 participants, actual
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Advanced Cancer
- Interventions
- vorinostat
- First posted
- 2009-05-25
- Last updated
- 2015-05-21
- Results first posted
- 2011-07-14
- Limitations and caveats
- Non-serious adverse events were only collected if they caused drug interruption, discontinuation, or dose reduction.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent of Participants With a Serious Drug-related Adverse Event (AE) | From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months) | A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose. A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent of Participants With a Serious Drug-related Adverse Event (AE) | From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months) | percent of participants | NUMBER |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Participants With a Serious Drug-related Adverse Event (AE) | Base Protocol 001 | 7.7 | percent of participants | ||
| Percent of Participants With a Serious Drug-related Adverse Event (AE) | Base Protocol 006 | 0 | percent of participants | ||
| Percent of Participants With a Serious Drug-related Adverse Event (AE) | Base Protocol 008 | 0 | percent of participants | ||
| Percent of Participants With a Serious Drug-related Adverse Event (AE) | Base Protocol 012 | 0 | percent of participants | ||
| Percent of Participants With a Serious Drug-related Adverse Event (AE) | Base Protocol 013 | 0 | percent of participants |
Source ClinicalTrials.gov
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Base Protocol 001 | 13 | |
| Overall Study | STARTED | Base Protocol 006 | 1 | |
| Overall Study | STARTED | Base Protocol 008 | 7 | |
| Overall Study | STARTED | Base Protocol 012 | 4 | |
| Overall Study | STARTED | Base Protocol 013 | 2 | |
| Overall Study | COMPLETED | Base Protocol 001 | 0 | |
| Overall Study | COMPLETED | Base Protocol 006 | 0 | |
| Overall Study | COMPLETED | Base Protocol 008 | 0 | |
| Overall Study | COMPLETED | Base Protocol 012 | 0 | |
| Overall Study | COMPLETED | Base Protocol 013 | 0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events207
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 001 (Vorinostat 400 mg Once Daily [QD]) | 3 | 13 | 4 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 006 (Vorinostat 200 mg Twice Daily [BID]) | 0 | 1 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 008 (Vorinostat 400 mg Once Daily [QD]) | 0 | 7 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 012 (Vorinostat 400 mg Once Daily [QD] 7/21) | 0 | 1 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 012 (Vorinostat 300 mg Twice Daily [BID] 3/7) | 0 | 1 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 14/21) | 0 | 1 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 7/21) | 0 | 1 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 013 (Vorinostat 200 mg Twice Daily [BID] 14/21) | 1 | 1 | 1 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Base Protocol 013 (Vorinostat 300 mg Twice Daily [BID] 3/7) | 0 | 1 | 0 |
| other | Abdominal pain lower | Gastrointestinal disorders | Base Protocol 001 (Vorinostat 400 mg Once Daily [QD]) | 0 | 13 | 0 |
1 to 10 of 207Source ClinicalTrials.gov
See all 207 adverse eventsAdverse event totals27
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Base Protocol 001 (Vorinostat 400 mg Once Daily [QD]) | ||
| Total, all-cause mortality | Base Protocol 006 (Vorinostat 200 mg Twice Daily [BID]) | ||
| Total, all-cause mortality | Base Protocol 008 (Vorinostat 400 mg Once Daily [QD]) | ||
| Total, all-cause mortality | Base Protocol 012 (Vorinostat 400 mg Once Daily [QD] 7/21) | ||
| Total, all-cause mortality | Base Protocol 012 (Vorinostat 300 mg Twice Daily [BID] 3/7) | ||
| Total, all-cause mortality | Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 14/21) | ||
| Total, all-cause mortality | Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 7/21) | ||
| Total, all-cause mortality | Base Protocol 013 (Vorinostat 200 mg Twice Daily [BID] 14/21) | ||
| Total, all-cause mortality | Base Protocol 013 (Vorinostat 300 mg Twice Daily [BID] 3/7) | ||
| Total, other adverse events | Base Protocol 001 (Vorinostat 400 mg Once Daily [QD]) | 6 | 13 |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 19951879 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00907738
GET https://conductscience.org/api/trials/v1/NCT00907738/events?page=2